H. Lundbeck A/S

HLUN A

Equity

ISIN DK0061804697 / Valor 119252584

Nasdaq Copenhagen Equities (2025-11-21)

DKK 33.50-0.30%

H. Lundbeck A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

H. Lundbeck A/S is a global pharmaceutical company headquartered in Denmark, with a presence in over 50 countries. The company specializes in developing and distributing innovative treatments for brain diseases, leveraging its production facilities in Denmark, France, and Italy, and research centers in Denmark and the United States. Since its listing on Nasdaq Copenhagen in 1999, Lundbeck has been primarily owned by the Lundbeck Foundation, which holds approximately 70% of its shares and supports medical research and educational initiatives. With a history spanning over 70 years, Lundbeck has been instrumental in providing therapies that address neurological and psychiatric disorders, impacting millions of patients worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue Growth

Lundbeck’s total revenue grew by 14% at constant exchange rates (CER) to DKK 12,258 million in the first half of 2025. This growth was primarily driven by strong performances in the United States and Europe, which contributed DKK 6,524 million and DKK 2,868 million respectively.

Strategic Brands Performance

The revenue from Lundbeck’s strategic brands increased by 21% CER to DKK 9,436 million, representing 77% of total revenue. Key contributors included Rexulti® with a 28% CER increase and Vyepti®, which surged by 56% CER.

EBITDA Growth

Adjusted EBITDA reached DKK 4,221 million, growing by 24% CER. This growth was fueled by the strong momentum of strategic brands and effective execution of Lundbeck’s Focused Innovator Strategy, leading to an improved EBITDA margin of 34.4%.

Raised Financial Guidance

Based on the solid first-half results, Lundbeck has raised its full-year 2025 revenue guidance to a growth of 11% to 13% CER, up from the previous forecast of 8% to 11%. Additionally, the adjusted EBITDA growth outlook has been increased to 16% to 21% CER, up from the earlier estimate of 8% to 14%.

Summarized from source with an LLMView Source

Key figures

-8.47%1Y

30.8%3Y

-14.1%5Y

Performance

49.6%1Y

35.5%3Y

34.8%5Y

Volatility